ORIC
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- ORIC Pharmaceuticals partners with Cancer Research UK to advance its potential first-in-class CIP2A-targeted therapy into clinical developmentOct 5, 2026
- ORIC Pharmaceuticals reported combination dose optimization data from a Phase 1b trial of Rinzimetostat in mCRPC patientsMar 27, 2026
- ORIC® Pharmaceuticals announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and continued to show potential best-in-class efficacy and safetyNov 14, 2025
- ORIC Pharmaceuticals to present initial data from Phase 1b trial of ORIC-944 combined with androgen receptor inhibitors in mCRPC patientsMay 27, 2025